A CDC study analyzing survey data from over 8,000 US adults found that 9.8% of Americans, or roughly 27 million people, used a GLP-1 medication in 2025. Nearly half of those users altered how they took the drug—skipping doses, delaying refills or taking smaller amounts than prescribed—and more than half of that group cited cost or availability as the reason. At least 23% of users took a compounded version of the drug, with another 9% unsure whether their medication was compounded.
arstechnica.com
· 2026-11-13
The FDA announced a new label warning for GLP-1 medications including Ozempic and Zepbound, flagging a rare eye condition that can cause sudden vision changes. The agency says the condition carries a risk of permanent damage in some patients.
fastcompany.com
· 2026-11-10
The FDA issued a drug safety communication requiring makers of GLP-1 drugs—including Ozempic, Wegovy, Zepbound and Mounjaro—to add a warning about a possible link to NAION, a rare condition that restricts blood flow to the optic nerve and can cause sudden, permanent vision loss. The agency says the exact mechanism is unknown, and the condition's rarity, combined with overlapping risk factors common among GLP-1 users like diabetes and high blood pressure, makes confirming a direct causal link difficult.
arstechnica.com
· 2026-11-10
The FDA issued a warning that GLP-1 medications may be associated with an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition causing sudden, painless vision loss in one eye that can be permanent. The agency said patients and caregivers using GLP-1 drugs should be aware of this potential risk.
science.slashdot.org
· 2026-11-10
Burger King's King Jr. meal sales rose 40% year over year last quarter, reaching a decade-high level, driven partly by upgraded chicken nuggets and a Dragon Ball Super promotion. President Tom Curtis said a growing number of adults are buying the kids' meals for smaller portions, with Circana data showing adult orders of kids' meals up 28% since 2019.
entrepreneur.com
· 2026-11-02
A new report cited by MIT Technology Review's The Checkup newsletter finds that global cases of anorexia nervosa and bulimia nervosa increased 71% between 1990 and 2023. Clinicians quoted in the report say they are already observing GLP-1 weight-loss drugs worsening disordered eating in some patients.
technologyreview.com
· 2026-10-30
Clinical psychologist Cheri Levinson of the University of Louisville says she is seeing more eating disorder patients with more severe symptoms than at any point in her nearly 20-year career, including growing numbers misusing GLP-1 weight-loss drugs. Separately, a study in JAMA Psychiatry led by Ruhai Bai of Children's Hospital of Nanjing Medical University estimated the incidence of anorexia and bulimia across 204 countries and territories from 1990 to 2023, finding rising global health burden from these conditions.
technologyreview.com
· 2026-10-30
New research shows that people taking GLP-1 weight-loss medications like Ozempic are cutting back on spending for certain foods, while increasing spending on fitness, supplements, and clothing. The study points to broader shifts in consumer habits tied to widespread use of these drugs, which can cost users hundreds of dollars monthly.
fastcompany.com
· 2026-10-27
University of Pennsylvania scientists analyzed roughly 150,000 Reddit posts from about 40,000 users to study self-reported effects of retatrutide, an experimental GLP-1 weight-loss drug not yet approved by regulators but obtained by some people in unapproved forms online. The study, published in JAMA Network Open, found that increased appetite was the most commonly reported symptom among classifiable complaints—contrary to the drug's hunger-suppressing design and the digestive issues emphasized in Phase 2 trials.
sciencedaily.com
· 2026-10-22
At the ARDD conference at Harvard, Novo Nordisk and Eli Lilly presented preliminary findings suggesting their GLP-1 receptor agonists, including semaglutide, may slow molecular markers of aging. Novo's study of 10,052 participants found proteomic clock differences of about two to three years between drug and placebo groups, with up to a four-year gap on a clock measuring heart-related proteins.
trial.medpath.com
· 2026-10-20
Following the August approval of Takeda's narcolepsy treatment Orzeyful (oveporexton), researchers are investigating whether orexin agonists could treat conditions beyond sleep disorders, including ADHD and other attention-related disorders. Takeda R&D president Andrew Plump compared the drug class's potential trajectory to GLP-1 drugs like Ozempic, which expanded from diabetes treatment into other therapeutic areas. The excitement builds on decades of research into orexins, brain peptides that influence sleep, mood, appetite and memory, first identified by scientists including Stanford's Luis de Lecea in the 1990s.
nature.com
· 2026-10-20
A TikTok account called WellWithHer is posting AI-generated images of weeping women alongside fabricated family text messages about secretly using GLP-1 weight-loss drugs like semaglutide and tirzepatide. The posts include screenshots of notifications from a medication-tracking app called Enzo, embedding product promotion within emotionally staged, fictional scenarios.
futurism.com
· 2026-10-19
GoKawiil